TORL BioTherapeutics, LLC has appointed Aran Maree, MD, an experienced physician and leader in the biopharmaceutical industry, as Chief Medical Officer. In addition, the company has initiated CATALINA-2, a global Phase 2 study of its novel Claudin 6 (CLDN6) targeted antibody-drug conjugate (ADC) TORL-1-23 in patients with CLDN6 positive platinum-resistant ovarian cancer.
Who to call at TORL BioTherapeutics, and when
A new leader at TORL BioTherapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day TORL BioTherapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at TORL BioTherapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
TORL BioTherapeutics
Location
Culver City, California, United States
About
TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for promising, and novel cancer targets.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment TORL BioTherapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Culver CityBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma